Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
FOXO4-DRI was designed to disrupt this interaction, allowing p53 to activate programmed cell death in senescent cells during laboratory studies
10.1016/0028-3908(96)84626-0 34 GawrylukJ
Regular meals, mindful drinking, and open communication with your clinician about your medications and activity levels are vital
The primary antibodies used included anti-ZO-1 (Abcam, ab307799, 1:5000), anti-Occludin (Abcam, ab216327, 1:5000), anti-ACSL4 (Abcam, ab155282, 1:10000), anti-TFR1 (ABclonal, A5865, 1:2000), anti-SLC7 A11 (Abcam, ab175186, 1:5000), anti-GPX4 (Abcam, ab125066, 1:5000), anti-VDAC2 (Proteintech, 116631-AP, 1:5000), anti-VDAC3 (Proteintech, 552601-AP, 1:5000), -tubulin (Proteintech, 100681-AP, 1:5000), and GAPDH (Proteintech, 104941-AP, 1:20000)
For patients pursuing serious, sustained weight management who meet clinical criteria
Presented for research literature review only Baek MC et al
